Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Sensitive Prostate Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT07052578
What this trial is testing

Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration

Who this might be right for
Prostate Cancer
AstraZeneca 400
Testing effectiveness (Phase 2)UnknownNCT06134271
What this trial is testing

Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Jianbin Bi 160
Testing effectiveness (Phase 2)WithdrawnNCT06060587
What this trial is testing

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

Who this might be right for
Prostate Cancer
Northwestern University
Testing effectiveness (Phase 2)Active Not RecruitingNCT04262154
What this trial is testing

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center 28
Not applicableLooking for participantsNCT07290270
What this trial is testing

Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)

Who this might be right for
Metastatic Prostate Cancer
Novartis Pharmaceuticals 170
Large-scale testing (Phase 3)Looking for participantsNCT06320067
What this trial is testing

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
University College, London 3,360
Not applicableStudy completedNCT05381311
What this trial is testing

Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study

Who this might be right for
Prostate CancerMetastatic Hormone-sensitive Prostate Cancer
Astellas Pharma Global Development, Inc. 1,020
Not applicableUnknownNCT05539300
What this trial is testing

PSMA Response in Metastasized Hormone Sensitive Prostate Cancer - Enzalutamide

Who this might be right for
Prostate Cancer
UMC Utrecht 150
Not applicableActive Not RecruitingNCT06010914
What this trial is testing

Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Bayer 100
Large-scale testing (Phase 3)Looking for participantsNCT07241416
What this trial is testing

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Jiangsu HengRui Medicine Co., Ltd. 206
Large-scale testing (Phase 3)Study completedNCT00242567
What this trial is testing

Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 522
Post-approval studies (Phase 4)Study completedNCT00219219
What this trial is testing

Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases

Who this might be right for
Prostate Cancer
Novartis
Large-scale testing (Phase 3)Active Not RecruitingNCT05794906
What this trial is testing

Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

Who this might be right for
Biochemically Recurrent Prostate Cancer
Bayer 985
Testing effectiveness (Phase 2)Study completedNCT02649855
What this trial is testing

Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer

Who this might be right for
Prostate CancerProstate NeoplasmsNeoplasms, Prostatic
National Cancer Institute (NCI) 74
Testing effectiveness (Phase 2)Active Not RecruitingNCT06991556
What this trial is testing

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Novartis Pharmaceuticals 168
Early research (Phase 1)Looking for participantsNCT04729114
What this trial is testing

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration Resistant Prostate CancerMetastatic Castration-sensitive Prostate Cancer
Astellas Pharma Global Development, Inc. 174
Early research (Phase 1)Looking for participantsNCT07339267
What this trial is testing

Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration-Resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc. 12
Not applicableActive Not RecruitingNCT06865547
What this trial is testing

ProA Study: ProActive Management Model in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated by Apalutamide

Who this might be right for
Prostate Cancer (Adenocarcinoma)
Yonghong Li 94
Testing effectiveness (Phase 2)UnknownNCT06505278
What this trial is testing

The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy

Who this might be right for
Prostate Cancer
Sun Yat-sen University 70
Testing effectiveness (Phase 2)WithdrawnNCT02065323
What this trial is testing

Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT

Who this might be right for
Prostate Cancer
Oscar Goodman, Jr.
Next Page